High blood caffeine levels in mci linked to lack of progression to dementia

Journal of Alzheimer's Disease

Volumn 30, Issue 3, 2012, Pages 559-572

  Cao, Chuanhai ^a,b,c,d   Loewenstein, David A ^e,f   Lin, Xiaoyang ^c   Zhang, Chi ^c   Wang, Li ^c   Duara, Ranjan ^e,f   Wu, Yougui ^a   Giannini, Alessandra ^e   Bai, Ge ^d   Cai, Jianfeng ^d   Greig, Maria ^e   Schofield, Elizabeth ^e   Ashok, Raj ^c   Small, Brent ^d   Potter, Huntington ^b,e   Arendash, Gary W ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; caffeine; coffee; dementia; immune response; mild cognitive impairment; plasma cytokines

Indexed keywords

CAFFEINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BLOOD ANALYSIS; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PREDICTION; PRIORITY JOURNAL;

EID: 84862869928     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111781     Document Type: Article

References (45)

1. van Gelder B, Buijsse B, Tijhuis M, Kalmijn S, Giampaoli S, Nissinen A, Kromhout D (2007) Coffee consumption is inversely associated with cognitive decline in elderly European men: The FINE Study. Eur J Clin Nutr 61, 226-232.
2. Ritchie K, Carriere I, de Mendonca A, Portet F, Dartigues J, Rouaud O, Barberger-Gateau P, AncelinM(2007) The neuroprotective effects of caffeine: A prospective population study (the Three City Study). Neurology 69, 536-545.
3. Eckelinen M, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M (2009) Midlife coffee and tea drinking and the risk of late life dementia:Apopulation- basedCAIDEstudy. J Alzheimers Dis 16, 85-91.
4. Laitala V, Kaprio J, Koskenvuo M, Raiha I, Rinne J, Silventoinen K (2009) Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr 90, 640-646.
5. Maia L, de Mendonca A (2002) Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 9, 377-382.
6. Sanchez-Ramos J, Song S, Sava V, Catlow B, Mori T, Dickson A, Lin X, Cao C, Arendash G (2009) G-CSF reverses cognitive impairment in Alzheimer's mice and decreases Alevels in both brain and blood. Neuroscience 163, 55-72.
7. Cao C, Arendash G, Dickson A, Mamcarz M, Lin X, Ethell D (2009) A-specific Th2 cells are sufficient to reverse cognitive impairment, cerebral angiopathy, and pro-inflammatory profiles in Alzheimer's transgenic mice. Neurobiol Dis 34, 63-70.
8. Selkoe D (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17, 1060-1065.
9. Arendash G, SchleifW, Rezai-Zadeh K, Jackson E, Zacharia L, Cracchiolo J, Shippy D, Tan J (2006) Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142, 941-952.
10. Arendash G, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tan J, Citron B, Lin X, Echeverria V, Potter H (2009) Caffeine reverses cognitive impairment and decreases brain Alevels in aged Alzheimer's mice. J Alzheimers Dis 17, 661-680.
11. Cao C, Cirrito J, Lin X,Wang L, Verges D, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash G, Holtzman D, Potter H (2009) Caffeine suppresses-amyloid levels in plasma and brain of Alzheimer's transgenic mice. J Alzheimers Dis 17, 681-697.
12. Zeitlin R, Patel S, Burgess S, Arendash GW, Echeverria V (2011) Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. Brain Res 1417, 127-136.
13. Higdon J, Frei B (2006) Coffee and health: A review of recent human research. Crit Rev Food Sci Nutr 46, 101-123.
14. Halvorsen B, Carlsen M, Phillips K, Bohn S, Holte K, Jacobs D, Blomhoff R (2006) Content of redox-active compounds (ie., antioxidants) in foods consumed in the United States. Am J Clin Nutr 84, 95-135.
15. Herder K, Erlund I, Kolb H, Martin S, Carstensen M, Koenig W, Sundvall J, Bidel S, Huha S, Tuomilehto J (2010) Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: A clinical trial. Am J Clin Nutr 91, 950-957.
16. Pham M, Yosida D, Yin G, Ohnaka K, Takayanagi R, Kono S (2010) The relationship of coffee and green tea consumption with high-sensitivity C-reactive protein in Japanese men and women. Clin Chem Lab Med 48, 849-854.
17. Bakuradze T, Boehm N, Janzowski C, Lang R, Hofmann T, Stockis JP, Albert FW, Stiebitz H, Bytof G, Lantz I, Baum M, Eisenbrand G (2011) Antioxidant-rich coffee reduces DNA damage, elevates glutathione status and contributes to weight control: Results from an intervention study. Mol Nutr Food Res 55, 793-797.
18. Cao C, Wang L, Lin X, Mamcarz M, Zhang C, Bai G, Nong J, Sussman S, ArendashGW(2011) Caffeine synergizes with another coffee component to increase plasma GCSF: Linkage to cognitive benefits in Alzheimer's mice. J Alzheimers Dis 25, 323-335.
19. Corley J, Jia X, Kyle J, Gow A, Brett C, Starr J, McNeill G, Deary I (2010) Caffeine consumption and cognitive function at age 70: The Lothian birth cohort 1936 study. Psychosomatic Med 72, 206-214.
20. Galvin J, Powlishta K, Wilkins K, McKeel D Jr, Xiong C, Grant E, Storandt M, Morris J (2005) Predictors of preclinical Alzheimer disease and dementia: A clinicopathologic study. Arch Neurol 62, 758-765.
21. Petersen R, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurology 58, 1985-1992.
22. Brooks L, Loewenstein DA (2010) Assessing the progression of mild cognitive impairment (MCI) to Alzheimer's disease: Current trends and future directions. Alzheimers Res Ther 2, 28.
23. Sheikh J, Yesavage J (1986) Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. In: Clinical Gerontology: A Guide to Assessment and Interventions, Brink TL, ed., The Haworth Press, NY, pp. 165-173.
24. Cummings J, Mega M, Gray K, Rosenberg-Thompson S, Carusi D, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of neuropathology in dementia. Neurology 44, 2308-2314.
25. Morris J (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414.
26. Folstein M, Folstein S, McHugh P (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the physician. J Psychiatr Res 12, 189-198.
27. Beekly D, Ramos E, Lee W, Deitrich W, Jacka M, Wu J, Hubbard J, Koepsell T, Morris J, Kukull W (2007) NIA Alzheimer's Disease Centers. The National Alzheimer's Coordinating Center (NACC) database: The Uniform Data Set. Alzheimer Dis Assoc Disord 21, 249-158.
28. Fuld P (1981) Fuld Object-Memory Evaluation, Illinois, Stoelting Co.
29. Benedict R, Schretlen D, Groninger L, Brandt J (1998) Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12, 43-55.
30. Loewenstein D, Amarilis Acevedo A, Small B, Agron J, Crocco E, Duara R (2009) Stability of different subtypes of mild cognitive impairment among the elderly over a two to three year follow-up period. Dement Geriatr Cogn Disord 17, 437-440.
31. Wechsler D (1997) The Wechsler Adult Intelligence Scale, edition 3., The Psychological Corporation, San Antonio, TX.
32. Monsch A, Bondi M, Butters N, Salmon D, Katzman R, ThalL (1992) Comparison of verbal fluency tasks in the detection of dementia of the Alzheimer's type. Arch Neurol 49, 1253-1258.
33. Spreen O, Strauss E (1998) A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, edition 2, Oxford University Press, New York, 1998, pp. 502-505.
34. Army Individual Test Battery (1944) Manual of directions and scoring. Washington, War Department, Adjutant General's Office, 1944.
35. Graham JE, Rockwood K, Beattie BL, McDowell I, Eastwood R, Gauthier S (1996) Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging. Neuroepidemiology 15, 246-256.
36. American Psychiatric, Association (1994) Diagnostic and statistical manual of mental disorders (4th edition), American Psychiatric Association, Washington.
37. Lee KS, Chung JH, Lee KH, Shin M-J, Oh BH, Hong CH (2008) Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment. Immunol Lett 121, 105-109.
38. Olson L, Humpel C (2010) Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Exp Gerontol 45, 41-46.
39. Fredholm B, Battig K, Holmen J, Nehlig A, Zvartau E (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51, 83-133.
40. Culm-Merdek KE, von Moltke LL, Harmatz JS, Greenblatt DJ (2005) Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. Br J Clin Pharmacol 60, 486-493.
41. Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, Ribera M, Villar AM (2008) Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 117, 198-202.
42. Forlenza OV, Diniz BS, Talib LL, Mendoca VA, Ojopi EB, Gattaz WF, Teixeira AL (2009) Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 28, 507-512.
43. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, Sockadar S, Richartz E, Koehler N, Bartels M, Buchkremer G, Schott K (2007) BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psych Res 41, 387-394.
44. Laske C, Stellow K, Stransky E, Seizer P, Akcay O, EschweilerGW, Leyhe T, GawazM(2008) Decreased plasma and CSF levels of stem cell factor in patients with early Alzheimer's disease. J Alzheimers Dis 15, 451-460.
45. Laske C, Stellos K, Stransky E, Leyhe T, Gawaz M (2009) Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early Alzheimer's disease. J Alzheimers Dis 17, 115-123.